Capital CS Group’s Immunocore IMCR Stock Holding History

Capital CS Group’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,422	Closed	-$252K	–	73
2022 Q4	$252K	Buy	+4,422	New	+$249K	0.28%	36

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital CS Group's IMCR Position: Q1 2023 in Review

Capital CS Group sold out of Immunocore (IMCR) in Q1 2023, closing a stake of 4,422 shares — an estimated $252K sold.

Capital CS Group first reported a position in IMCR in Q4 2022 and held it in 1 quarter. The position peaked at $252K in Q4 2022. 109 funds tracked by Wall St. Rank hold IMCR as of Q1 2023.

Capital CS Group reported no remaining Immunocore position as of Q1 2023 after selling out during the quarter.
Capital CS Group sold 4,422 Immunocore shares in Q1 2023, an estimated $252K.
Capital CS Group first reported a position in Immunocore in Q4 2022 and held it in 1 quarter.
Capital CS Group's Immunocore position peaked at $252K in Q4 2022.
109 funds tracked by Wall St. Rank held Immunocore as of Q1 2023.

Based on Capital CS Group's 13F filing for Q1 2023, filed 7 Apr 2023.